Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications.

Abstract

The management of laryngeal and tracheal stenosis continues to challenge us, despite advances in surgical techniques and better understanding of the wound healing process. Injury to the airway mucosa is the inciting event, regardless of the cause of the stenosis. Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis. It can inhibit cell division, protein synthesis, and fibroblast proliferation. Topical application of mitomycin-C (0.4 mg/mL) was used as an adjuvant treatment in the endoscopic laser management of laryngeal and tracheal stenosis in 15 patients. Fourteen patients (93%) have shown improvement of their airway and resolution of their preoperative symptoms. After a mean follow-up of 18 months, no complication was noted with regard to the application of mitomycin-C. This study gives promising findings on the efficacy and safety of mitomycin-C as an adjuvant treatment in the management of selected cases of laryngeal and tracheal stenosis.

• Authors: R Rahbar, S M Shapshay, G B Healy
• Journal: The Annals of otology, rhinology, and laryngology (Ann Otol Rhinol Laryngol) Vol. 110 Issue 1 Pg. 1-6 (Jan 2001) ISSN: 0003-4894 [Print] United States
• PMID: 11201800 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Antimetabolites
• Nucleic Acid Synthesis Inhibitors
• Mitomycin

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Antimetabolites (administration & dosage, adverse effects)
• Child
• Child, Preschool
• Cicatrix (prevention & control)
• Combined Modality Therapy
• Female
• Humans
• Intraoperative Period
• Laryngoscopy
• Laryngostenosis (surgery)
• Laser Therapy
• Male
• Middle Aged
• Mitomycin (administration & dosage, adverse effects)
• Nucleic Acid Synthesis Inhibitors (administration & dosage, adverse effects)
• Prospective Studies
• Recurrence
• Tracheal Stenosis (surgery)
• Wound Healing